Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade

Table 1

Patients characteristics.

Patients	126
Age, median (range)	59 (15–86)
Gender
Male	69 (55%)
Female	57 (45%)
Primary melanoma
Breslow	Median 3.05 mm (0.2–20)
Cutaneous	76 at least
Acral	10
Mucosal	0
Unknown	11
Ulcerated	29/58 documented
AJCC stage
IIIB	57 (45%)
IIIC	69 (55%)
Satellites	22 (17%)
Number of involved LNs, mean (range)	2.4 (0–17)
Adjuvant radiotherapy	56 (44%)